Latency-Associated Nuclear Antigen 2 (LANA2) antibody
Reactivity: Human Herpesvirus 8 (HHV-8)
WB, IF, IP, IHC, ELISA
Host: Mouse
Monoclonal
CM-A807
unconjugated
1 image
-
- Target
- Latency-Associated Nuclear Antigen 2 (LANA2)
- Reactivity
- Human Herpesvirus 8 (HHV-8)
- Host
- Mouse
- Clonality
- Monoclonal
- Application
- Western Blotting (WB), Immunofluorescence (IF), Immunoprecipitation (IP), Immunohistochemistry (IHC), ELISA
- Specificity
- Reacts with human and murin Kaposi's sarcoma-associated herpes virus (KSHV) ~66-70 kDa LANA2 protein and shows no cross-reactivity to cellular proteins
- Purification
- Purified (protein G)
- Immunogen
- Recombinant LANA2 fusion protein
- Clone
- CM-A807
- Isotype
- IgG1 kappa
-
- Application Notes
-
Working dilution: Optimal dilution should be determined by the end user.
The following are guidelines only :
- IHC : 1/10 to1/2000 - IF : 2 to 4 μg/mL - IP : 2 to 4 μg/mL - WB : 2 to 4 μg/mL - Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 2 mg/mL
- Storage
- 4 °C/-20 °C
- Storage Comment
- Short term storage at +4°C. For extended periods store in aliquots at -20°C. Antibodies are guaranteed for 6 month from date of receipt.
- Expiry Date
- 6 months
-
- Target
- Latency-Associated Nuclear Antigen 2 (LANA2)
- Target Type
- Viral Protein
- Background
- LANA2 (latency-associated nuclear antigen) is an inhibitor of p53-induced transcription in reporter assays and may be an apoptosis antagonist.It is a nuclear protein associated with Kaposi's sarcoma-associated herpes virus (KSHV), or human herpes virus 8.It is found in abundance in the nuclei of cultured cells from KSHV-infected hematopoietic tissues, such as PEL (primary effusion lymphoma) and CD (multicentric Castleman's disease).It does not appear to be expressed in KS (Kaposi's sarcoma) lesions.
-
You are here:
